ELEAF (El.En. SpA) ROCE %: 35.35% (As of Mar. 2026)


ELEAF El.En. SpA ELEAF
74 GF Score
Price $18.50
GF Value $15.64
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is El.En. SpA ROCE %?

El.En. SpA ELEAF 74 ROCE % is 35.35% as of Mar. 2026. GuruFocus rates ELEAF with a GF Score™ of 74/100 and a GF Value™ of $15.64 (Modestly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. El.En. SpA's annualized ROCE % for the quarter that ended in Mar. 2026 was 35.35%.

El.En. SpA  (OTCPK:ELEAF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

El.En. SpA ROCE % Related Terms

El.En. SpA ROCE % Historical Data

* Premium members only.

The historical data trend for El.En. SpA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

El.En. SpA ROCE % Chart

El.En. SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.19 20.40 19.03 16.71 15.44

El.En. SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.30 22.68 22.91 25.06 35.35
ELEAF
74GF Score
El.En. SpA ELEAF
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

El.En. SpA ROCE % Calculation

El.En. SpA's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=87.957/( ( (775.624 - 178.733) + (735.224 - 192.498) )/ 2 )
=87.957/( (596.891+542.726)/ 2 )
=87.957/569.8085
=15.44 %

El.En. SpA's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=91.812/( ( (735.224 - 192.498) + (0 - 23.262) )/ 2 )
=91.812/( ( 542.726 + -23.262 )/ 2 )
=91.812/259.732
=35.35 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 35.35% mean?
El.En. SpA (ELEAF) has a ROCE % of 35.35% as of Mar. 2026.
Is El.En. SpA's ROCE % too high?
El.En. SpA's current ROCE % is 35.35%. The Medical Devices & Instruments industry median ROCE % is 2.23. El.En. SpA's value of 35.35% is 1485.2% above this industry median. Overall, El.En. SpA has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does El.En. SpA's ROCE % compare to ABT and SYK?
El.En. SpA's ROCE % of 35.35% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. El.En. SpA's value of 35.35% is 1485.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. El.En. SpA's current ROCE % of 35.35% is 1485.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. El.En. SpA's current ROCE % is 35.35%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is El.En. SpA stock overvalued right now?
Based on GuruFocus' analysis, El.En. SpA (ELEAF) is currently considered Modestly Overvalued. The stock's GF Value™ is $15.64, compared to a current price of $18.50 — trading 18.3% above its estimated fair value. The current ROCE % is 35.35% and 1485.2% above the Medical Devices & Instruments industry median of 2.23. El.En. SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For El.En. SpA (ELEAF), the current ROCE % is 35.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is El.En. SpA (ELEAF) Overvalued in 2026?

Based on GuruFocus' analysis, El.En. SpA stock appears to be overvalued. The current stock price of $18.50 is trading 18.3% above its estimated GF Value™ of $15.64. GuruFocus considers El.En. SpA to be Modestly Overvalued.

Key valuation signals for ELEAF:

  • ROCE %: 35.35%
  • GF Value™: $15.64 vs. price of $18.50 (18.3% above fair value)
  • GF Score™: 74/100 with 6 warning signs
  • Industry Position: 1485.2% above the Medical Devices & Instruments median

No single metric tells the full story. See the ELEAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

El.En. SpA Business Description

Address Via Baldanzese No. 17, Calenzano, Florence, ITA, 50041
El.En. SpA is engaged in the research and development, manufacturing, distribution, and sales of laser systems. The company operates in two divisions: medical and industrial. In the medical division, the application of laser is used as a healing treatment for aesthetic, surgical, physiotherapy and dental. Industrial division develops solutions for laser material processing applications through cutting, marking, laser sources and restoration. The company generates the majority of its revenue from the medical division. Geographically, it derives maximum revenue from the Rest of the World.
74GF Score

Get the complete analysis for ELEAF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.50
Price
$15.64
GF Value